Literature DB >> 16375697

Signal transducer and activator of transcription 5 (STAT5), a crucial regulator of immune and cancer cells.

Ilka Wittig1, Bernd Groner.   

Abstract

STAT5 belongs to a small family of transcription factors with dual functions. The seven signal transducers and activators of transcription (STAT) act as signaling components between the plasma membrane and the nucleus, and as transcription factors with specific DNA binding ability in the nucleus. STAT5 regulates the expression of genes, which determine important cellular phenotypes. It can promote proliferation and inhibit apoptosis, but is also involved in the regulation of differentiation between specific gene expression. STAT5 can also contribute to the transformed phenotype. In many leukemias and some solid tumors, STAT5 is constitutively activated through receptors or receptor associated tyrosine kinases and contributes to the survival and the proliferation of malignant cells. STAT5 activity appears to be limiting for these phenotypes. Inhibition of STAT5 in these tumor cells results in growth arrest and apoptosis. Targeting of STATs and other downstream mediators of oncogenic tyrosine kinases provides a promising strategy for tumor therapy, which might be refractory to resistance mechanisms incapacitating tyrosine kinase inhibitors. The well-studied steps in the activation of STAT5 and its roles in different subcellular compartments suggest original interference strategies, which could be used to inhibit its function. The challenge for drug developers will be the exploitation of defined protein-protein or protein-DNA interactions as targets of inhibition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16375697     DOI: 10.2174/156800805774912999

Source DB:  PubMed          Journal:  Curr Drug Targets Immune Endocr Metabol Disord        ISSN: 1568-0088


  12 in total

Review 1.  The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.

Authors:  Sylvane Desrivières; Christian Kunz; Itamar Barash; Vida Vafaizadeh; Corina Borghouts; Bernd Groner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

2.  Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression.

Authors:  Seungchan Yang; Kyungho Park; James Turkson; Carlos L Arteaga
Journal:  Exp Cell Res       Date:  2007-09-08       Impact factor: 3.905

3.  Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans.

Authors:  Jesse Rowley; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

4.  Preconditioning mediated by sublethal oxygen-glucose deprivation-induced cyclooxygenase-2 expression via the signal transducers and activators of transcription 3 phosphorylation.

Authors:  Eun J Kim; Ami P Raval; Miguel A Perez-Pinzon
Journal:  J Cereb Blood Flow Metab       Date:  2008-04-09       Impact factor: 6.200

5.  Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.

Authors:  Phuoc T Tran; Alice C Fan; Pavan K Bendapudi; Shan Koh; Kim Komatsubara; Joy Chen; George Horng; David I Bellovin; Sylvie Giuriato; Craig S Wang; Jeffrey A Whitsett; Dean W Felsher
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

6.  The protein arginine methyltransferases CARM1 and PRMT1 cooperate in gene regulation.

Authors:  Markus A Kleinschmidt; Gundula Streubel; Birgit Samans; Michael Krause; Uta-Maria Bauer
Journal:  Nucleic Acids Res       Date:  2008-04-15       Impact factor: 16.971

7.  Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.

Authors:  Kazuyuki Takakuma; Naohisa Ogo; Yutaka Uehara; Susumu Takahashi; Nao Miyoshi; Akira Asai
Journal:  PLoS One       Date:  2013-08-16       Impact factor: 3.240

8.  Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin.

Authors:  Gerhard Hamilton
Journal:  Cancers (Basel)       Date:  2014-07-08       Impact factor: 6.639

9.  In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells.

Authors:  Thomas Cuny; Caroline Zeiller; Martin Bidlingmaier; Céline Défilles; Catherine Roche; Marie-Pierre Blanchard; Marily Theodoropoulou; Thomas Graillon; Morgane Pertuit; Dominique Figarella-Branger; Alain Enjalbert; Thierry Brue; Anne Barlier
Journal:  Endocr Relat Cancer       Date:  2016-06-07       Impact factor: 5.678

10.  The Selectivity of Fosfosal for STAT5b over STAT5a is Mediated by Arg566 in the Linker Domain.

Authors:  Julian Gräb; Thorsten Berg
Journal:  Chembiochem       Date:  2020-05-08       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.